| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698115 | Clinical Oncology | 2015 | 8 Pages |
Abstract
IMRT with simultaneous integrated boost is safe and well tolerated in an unselected population. Most dose specifications are achievable. Excellent locoregional control and survival outcomes are achievable outside of a clinical trial setting.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
A. Yates, S. Carroll, A. Kneebone, R. Tse, L. Horvath, C. Byrne, M. Solomon, G. Hruby,